Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O75976
UPID:
CBPD_HUMAN
Alternative names:
Metallocarboxypeptidase D; gp180
Alternative UPACC:
O75976; B7Z7T9; B7ZAU4; F5GZH6; O15377; Q86SH9; Q86XE6
Background:
Carboxypeptidase D, also known as Metallocarboxypeptidase D or gp180, plays a crucial role in protein processing pathways. This enzyme is involved in the cleavage of C-terminal amino acids, facilitating various biological processes. Its presence and activity are essential for maintaining cellular functions and homeostasis.
Therapeutic significance:
Understanding the role of Carboxypeptidase D could open doors to potential therapeutic strategies. Its pivotal function in protein metabolism suggests that modulating its activity could offer new avenues for treating diseases where protein processing is disrupted.